BRIEF published on 07/15/2024 at 09:35, 1 year 4 months ago Amolyt Pharma, a Portfolio Company of Andera Partners, Acquired by AstraZeneca Acquisition Biopharmaceuticals AstraZeneca Amolyt Pharma Rare Diseases
PRESS RELEASE published on 07/15/2024 at 09:30, 1 year 4 months ago Andera Partners’ portfolio company Amolyt Pharma completes acquisition by AstraZeneca Andera Partners' portfolio company Amolyt Pharma has been acquired by AstraZeneca for $1.05 billion, enhancing AstraZeneca's Rare Disease late-stage pipeline and bone metabolism franchise Acquisition Biopharmaceutical AstraZeneca Amolyt Pharma Andera Partners
BRIEF published on 07/09/2024 at 08:15, 1 year 4 months ago Andera Partners Co-Leads €63 Million Series A for Biotech SciRhom Series A Financing Biopharmaceuticals Andera Partners Autoimmune Disorders SciRhom
PRESS RELEASE published on 07/09/2024 at 08:10, 1 year 4 months ago Andera Partners co-leads a €63 million Series A round for Munich-based autoimmune biotech SciRhom Andera Partners co-leads a €63 million Series A round for Munich-based autoimmune biotech SciRhom to advance novel iRhom2 antibody therapy towards clinical proof-of-concept Andera Partners SciRhom Autoimmune Biotech Series A Round IRhom2 Antibody
BRIEF published on 03/14/2024 at 11:15, 1 year 8 months ago Andera Partners’ Portfolio Company Tubulis Secures €128 Million in Series B2 Financing Clinical Trials Andera Partners Tubulis Series B2 Financing ADC Development
PRESS RELEASE published on 03/14/2024 at 11:10, 1 year 8 months ago Andera Partners’ portfolio company Tubulis closes upsized €128 Million Series B2 to accelerate the development of its ADC Pipeline Andera Partners’ portfolio company Tubulis closes upsized €128 Million Series B2 financing to accelerate ADC pipeline development Andera Partners Tubulis €128 Million Series B2 ADC Pipeline Biotech Financing
BRIEF published on 03/14/2024 at 09:05, 1 year 8 months ago AstraZeneca Acquires Amolyt Pharma for up to $1.05 Billion Acquisition Biopharmaceutical AstraZeneca Amolyt Pharma Rare Diseases
PRESS RELEASE published on 03/14/2024 at 09:00, 1 year 8 months ago Amolyt Pharma, an Andera Partners’ portfolio company, announces its sale to AstraZeneca Amolyt Pharma, a clinical-stage biopharmaceutical company specializing in therapeutic peptides, is being acquired by AstraZeneca for $1.05 billion. The transaction is expected to close in Q3 2024 Acquisition AstraZeneca Amolyt Pharma Therapeutic Peptides Rare Endocrine Diseases
PRESS RELEASE published on 05/15/2023 at 09:00, 2 years 6 months ago Andera Partners co-leads a €40 million Series A of Dualyx, a Belgian biotech developing novel Treg therapies for autoimmune diseases
PRESS RELEASE published on 05/10/2023 at 09:00, 2 years 6 months ago Andera Partners appoints Stefan Keitel Senior Advisor DACH region further strengthening its presence in the German, Austrian and Swiss private equity markets
Published on 12/05/2025 at 02:35, 10 hours 22 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 11 hours 57 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 13 hours 52 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 13 hours 57 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 12:05, 52 minutes ago Cango Inc. Announces November 2025 Bitcoin Production and Mining Operations Update
Published on 12/05/2025 at 12:00, 57 minutes ago CGTN：Strengthening cultural ties: Peng Liyuan, Brigitte Macron visit Beijing People's Art Theatre
Published on 12/05/2025 at 12:00, 57 minutes ago Iute Group: Successful Issue of Additional EUR 2025/2030 Bonds – Circulating Volume Increased to EUR 160 Million
Published on 12/05/2025 at 11:14, 1 hour 43 minutes ago Halfords Group PLC: Director/PDMR Shareholding
Published on 12/05/2025 at 10:30, 2 hours 27 minutes ago Tradegate Exchange and Börse Berlin merge to form Tradegate BSX
Published on 12/05/2025 at 08:45, 4 hours 12 minutes ago Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 18 hours 57 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 19 hours 12 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 19 hours 13 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day 5 hours ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
